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1
The Status of HIV Prevention in the United States
The science is clear: HIV prevention can and does save lives.1-4  Scores of  
scientific studies have identified effective prevention interventions for numerous  
populations,5-10 and it is estimated that prevention efforts have averted more  
than 350,000* HIV infections in the United States to date.4  In addition to the  
lives saved from HIV, it is estimated that more than $125 billion in medical costs 
alone have been averted.11,12         
But the HIV crisis in America is far from over.  CDC’s latest estimates suggest that 
more than 56,000 Americans become infected each year13—one person every  
9 ½ minutes—and that more than one million people in this country are now  
living with HIV.14  Far too many Americans remain at risk for HIV, especially African 
Americans, Latinos, and gay and bisexual men of all races.  CDC estimates that  
roughly 1 in 5 people infected with HIV in the United States is unaware of his or 
her infection and may be unknowingly transmitting the virus to others.14
The heavy burden of HIV in the United States is neither inevitable nor acceptable.  
It is possible to end the U.S. epidemic, but such an achievement will require that 
we dramatically expand access to proven HIV prevention programs, make tough 
choices about directing available resources, and effectively integrate new HIV 




























































Estimated Number of New HIV Infections 
and Persons Living with HIV/AIDS, 1977-2006 
Estimates of New Infections, 2006, By Race/Ethnicity, Risk Group, and Gender, 
for the Most Affected U.S. Subpopulations* 
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  *Subpopulations representing 2 percent or less of the overall U.S. epidemic are not reflected in this chart.
**The term men who have sex with men is used in CDC surveillance systems because it indicates the behaviors that transmit HIV infection, rather 
   than how individuals self-identify in terms of their sexuality.
Gay and bisexual men of all races and black heterosexuals account for the greatest number of 
new HIV infections in the United States.
Despite continued increases in the number of people 
living with HIV/AIDS over time, and more opportunities 
for transmission, HIV prevention efforts have helped to 
keep the number of new infections stable. 
“It’s imperative that we  
confront a serious threat  
to the health of our nation.   
And that threat is  
complacency – a false  
sense of security, a false 
sense of calm that hides 
what remains a serious  
epidemic.  The fact is that, 
right here in the United 
States, every 9 1/2  minutes 
someone’s mother, so e-
one’s daughter, someone’s 
son, someone’s father, or 
friend, becomes infected 
with HIV.” 
Dr. Kevin Fenton 
Director, CDC’s National Center 
for HIV/AIDS, Viral Hepatitis,  
STD, and TB Prevention
                  
*A conservative estimate examining the period 1991 to 2006.









    
 
    




     
 
 
    
  





    
 
           2           SECTION 1 | HIV Prevention Works   
HIV Prevention Works 
After almost three decades of experience with HIV in 
the United States, we know that prevention works. 
Our national investment in HIV prevention has contributed 
to dramatic reductions in the annual number of new 
infections since the peak of the epidemic in the mid­
1980s, and an overall stabilization of new infections 
over the past decade.13  Given continued increases in the 
number of people living with HIV, this stabilization is in 
itself a sign of progress (see box, “Measuring the Suc­
cess of Prevention,” on page 3). Other important signs 
of progress include dramatic declines in mother-to-child 
HIV transmission and reductions in new infections among 
injection drug users and heterosexuals over time. 
HIV prevention has also generated substantial economic 
benefits. For every HIV infection that is prevented, an
estimated $355,000 is saved in the cost of providing 
lifetime HIV treatment,12 resulting in significant cost-sav­
ings for the health care system.4 
CDC’s Prevention Efforts 
While significant progress has been made, much more 
must be done. CDC pursues three major strategies to 
reduce the toll of HIV in the United States: 
n Supporting prevention programs.  CDC provides 
funding and technical assistance to help state and 
local health departments and community-based 
organizations implement evidence-based HIV 
prevention programs. 
n Tracking the epidemic.  CDC oversees surveillance 
systems to track new HIV infections and HIV and 
AIDS diagnoses across the United States, as well as 
the level of risk behaviors and access to prevention in 
high-risk populations. This information helps ensure 
that funding is directed to the populations and 
communities most in need. 
n Identifying new prevention interventions.  CDC 
works with research partners to identify and develop 
new prevention interventions that address the specific 
needs of populations at risk, so that they can be 
broadly disseminated and integrated into local HIV 
prevention efforts. 
Proven HIV Prevention Interventions 
We know more than ever before about what works to 
prevent HIV.  Research has led to a growing number of 
proven, cost-effective approaches to reduce the risk of HIV 
infection. In the United States, proven strategies include: 
n HIV testing. Learning one’s HIV status has been 
shown to result in substantial reductions in risk 
behavior.15  Testing is a critical component of 
prevention efforts because when people learn they 
are infected, they can take steps to protect their own 
health and prevent HIV transmission to others. 
n Prevention programs for people living with HIV.
Individual and small-group interventions delivered by 
health care providers, peers, and others have been 
shown to significantly reduce risk behaviors among 
people who have been diagnosed with HIV to help 
ensure they do not transmit the virus to others.16 
To date, CDC has identified 10 proven interventions 
for HIV-positive people that meet stringent criteria 
for efficacy and scientific rigor.17 
n Prevention programs for people at risk of HIV 
infection.  Individual, small-group, and community
interventions for people who are at risk of HIV 
infection significantly reduce risk behavior in diverse 
populations, including men who have sex with 
men,* heterosexual women and men, drug users, 
and youth.16  To date, CDC has identified 53 proven 
interventions for populations at high risk that meet 
stringent criteria for efficacy and scientific rigor.17 
n Partner services.  Partner services reduce the spread 
of HIV by facilitating the confidential identification 
and notification of partners who may have been 
unknowingly exposed to HIV, providing them with 
HIV testing, and linking them to medical care, 
prevention programs, and other services.18,19 
n Antiretroviral therapy.  Antiretroviral medications 
significantly reduce the risk of HIV transmission from 
HIV-infected pregnant women to their infants20,21 
*The term men who have sex with men is used in CDC surveillance systems because it indicates the behaviors that transmit HIV infection, rather than 
how individuals self-identify in terms of their sexuality. 
                   
 
 
       
 
    
 
   
    
 
 
    
 
 
















    
 
 
3 SECTION 1 | HIV Prevention Works   
and, when started promptly, can reduce the risk of 
infection after exposure to HIV.22,23  Researchers are 
also studying whether antiretroviral medicines given
before risk behavior occurs can reduce the chances 
of becoming infected with HIV24 (see more detailed
discussion on page 7). 
n Substance abuse treatment. Effective substance 
abuse treatment that helps drug users stop injecting 
eliminates the risk of HIV transmission through 
injection drug use and has been shown to reduce 
risky sexual behaviors.25,26 
n Access to condoms and sterile syringes.  In order 
for HIV prevention efforts to work, people who are 
living with, or at risk for, HIV need to have access to 
effective tools that enable them to reduce the risk of 
HIV transmission. For example, research has shown 
that increasing the availability of condoms27 and 
sterile syringes25 is associated with significant 
reductions in HIV risk. 
n Screening and treatment for other sexually 
transmitted infections. Sexually transmitted 
infections (STIs) increase an individual’s risk of acquiring 
and transmitting HIV28, and STI treatment may reduce 
HIV viral load.29,30,31  Therefore, STI screening and treat­
ment may reduce risk for HIV transmission. 
“The harsh mathematics of this epidemic 
proves that prevention is essential to 
expanding treatment. Treatment without 
prevention is simply unsustainable.” 
Bill Gates 
Co-chair, Bill & Melinda Gates Foundation 
Measuring the Success of Prevention: 
How Do You Count What Doesn’t 
Occur? 
Trying to measure what does not occur – the number of 
infections prevented, illness avoided, and lives saved – is a 
difficult challenge in HIV prevention. Three key indicators 
can be used to gauge the impact of HIV prevention efforts 
on the U.S. epidemic: 
n Trends in HIV infections.  Examining increases or 
decreases in estimated HIV infections over time is an
important indicator of overall prevention progress, but 
may mask important signs of success. For example, 
new HIV infections in the United States declined 
dramatically after the mid-1980s, and overall have 
remained roughly stable over the past decade.13  This 
stabilization, however, is an important sign of success.
With more people living with HIV than ever before 
thanks to effective HIV medications,32 there are more 
opportunities for transmission. Yet the number of 
infections has not increased, indicating that HIV 
testing, prevention, and treatment programs are 
effectively reducing the rate of transmission 
(see graph on page 1). 
n HIV transmission rates. A useful measure of 
prevention success is the estimated rate of HIV 
transmission, which indicates the likelihood that 
an HIV-infected individual will transmit the virus 
to others. CDC estimates that there were 5 
transmissions per 100 persons living with HIV in 
the United States in 2006. This means that the 
vast majority (at least 95%) of people living with HIV 
did not transmit the virus to others that year.  This 
represents an 89 percent decline in the estimated 
rate of HIV transmission since the mid-1980s.33 
n Modeling of infections averted.  Scientists have 
developed models to estimate the number of HIV 
infections that have been averted because of HIV 
prevention efforts, based on the trajectory of the 
epidemic before prevention programs were initiated. 
These models suggest that hundreds of thousands of 
HIV infections have been prevented because of the 







































Estimated Number of New HIV Infections 
and Persons Living with HIV/AIDS, 1977-2006 
New HIV infections 
People living with 
HIV/AIDS
JAMA 2008;300(5):520-529
Campsmith M, et al. CROI 2009
Despite continued increases in the number of people 
living with HIV/AIDS over time, and more opportunities 
for transmission, HIV prevention efforts have helped to 
keep the number of new infections stable.
 
        
 




    
 
  





4                   SECTION 2 | Too Many Americans are Still at Risk for HIV 
Too Many Americans are 
Still at Risk for HIV 
Despite substantial knowledge of how to effectively 
prevent HIV, there is evidence that populations at greatest 
risk are not being sufficiently reached by proven prevention 
interventions and that Americans are becoming 
complacent about the threat of HIV: 
n Too many people at risk for HIV do not have 
access to HIV prevention programs.  For example, 
80 percent of gay and bisexual men report not 
being reached by either individual- or group-based 
prevention programs in the prior year.35 
n Too few people infected with HIV are aware of 
their infection.  CDC data indicate that roughly 
1 in 5 people infected with HIV – more than 200,000 
individuals – do not know they have the virus.14 
Because the majority of new sexually transmitted HIV 
infections are transmitted by those unaware of their 
infection, undiagnosed infection remains a significant 
factor fueling the HIV epidemic.36 
n Too many Americans have become complacent 
about HIV.  A recent survey by the Kaiser Family 
Foundation found that the percentage of Americans 
who rank HIV as a major health problem has declined 
precipitously over the past decade.37  Even more 
troubling are studies showing that some of the 
populations with the highest rates of infection 
(including men who have sex with men and African 
Americans) either do not recognize their risk or 



































































Estimates of New Infections, 2006, By Race/Ethnicity, Risk Group, and Gender, 
for the Most Affected U.S. Subpopulations* 
Gay and bisexual men of all races and black heterosexuals account for the greatest number of 































*Subpopulations representing 2 percent or less of the overall U.S. epidemic are not reflected in this chart. 
**The term men who have sex with men is used in CDC surveillance systems because it indicates the behaviors that transmit HIV infection, rather 
   than how individuals self-identify in terms of their sexuality. 





     
     
 
 
      
        
        
       
 
 
     
 
    
 
     













5 SECTION 2 | Too Many Americans are Still at Risk for HIV 
Populations at Greatest Risk 
Gay and bisexual men of all races and racial/ethnic 
minorities are disproportionately affected by HIV, comprising
the largest number of new HIV infections, HIV and AIDS 
diagnoses, and deaths among people with AIDS in the 
United States. Injection drug users also remain at 
considerable risk, but new HIV infections have been 
declining in this group.13 
Men Who Have Sex with Men 
While HIV now affects a more diverse population than 
ever before, gay and bisexual men of all races remain the 
group most severely and disproportionately impacted by 
this epidemic. 
n MSM transmission represents 53 percent of 
estimated new infections, followed by transmission 
through heterosexual sex (31%) and injection drug 
use (12%).13 
n MSM is the only risk group in the United States 

in which infections are increasing – the annual 

number of new infections has increased steadily 

since the early 1990s.13
 
n White MSM continue to represent a greater number
of new HIV infections annually than any other 
population, followed closely by black MSM – who 
are one of the most disproportionately affected 
subgroups in the United States.39 
African Americans 
In addition to disparities by risk group, there are also 
severe racial/ethnic disparities in the U.S. HIV epidemic, 
with blacks bearing the heaviest burden. While preven­
tion efforts have helped maintain stability in the level of 
HIV infection among blacks overall since the early 1990s,13 
the ongoing toll in many black communities across the 
nation is staggering: 
n While blacks represent 12 percent of the U.S. 
population, they account for nearly half (45%) of 
new HIV infections.13 
n Among African Americans, black MSM are the 
hardest-hit subpopulation.39  Studies have found that 
almost 50 percent of black MSM are infected in 
some cities.40 
n Heterosexual transmission also accounts for a 
substantial proportion of the black HIV epidemic, 
with black women most affected. Black heterosexual 
women represent 14 percent of all new HIV 
infections in the United States, and black 
heterosexual men account for 6 percent.39 
n Black women, the majority of whom are infected 
through heterosexual sex, have an HIV infection 
rate that is nearly 15 times as high as that of 
white women.39 
Latinos 
While not as severely impacted as blacks, Hispanics are 
also disproportionately affected by HIV. 
  n  Hispanics represent approximately 13 percent of the 
U.S. population, but account for 17 percent of all 
new HIV infections in the United States each year.  
The overall HIV infection rate for Hispanics is three 
times as high as that of whites (29.3 per 100,000 
population versus 11.5).13 
 n   Among Hispanics, MSM are most heavily impacted, 
followed by women infected heterosexually.39 
“We need to be able to talk about HIV 
as we talk about jobs, as we talk about 
housing, as we talk about civil rights. 
We all have a responsibility to break the 
silence about this disease.” 
Dr. Dorothy Height 
Chair and President Emerita,
National Council of Negro Women 
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What Will Determine the 
Future Course of the U.S. 
HIV Epidemic 
Dramatically reducing HIV infection rates in the United 
States will require a major new commitment to HIV 
prevention. The future course of the U.S. HIV epidemic will 
be determined by the scale of our response, and by how 
effectively we utilize proven and emerging approaches to 
preventing HIV. 
1. Scale of the Response 
Research suggests that the size of the nation’s investment 
in HIV prevention predicts future infection rates. Histori­
cally, increases in federal investment in HIV prevention 
have been followed by declines in infection rates.41  In 
recent years, federal resources have not been able to 
keep pace with the epidemic. Since 2002, CDC’s HIV 
prevention budget (approximately $750 million in FY09) 
has declined by almost 20 percent in real dollars (adjusted 
for inflation), and prevention currently accounts for 4 
percent of all federal HIV/AIDS spending on the domestic 
epidemic.4,42,43 
At the request of Congress, CDC recently estimated the 
impact of additional investment on the epidemic. These 
estimates projected that with an additional $877 million 
in annual HIV prevention funding, the reach of prevention 
programs could be significantly expanded and transmission
rates could be cut in half in just over a decade, resulting 
in dramatic cost-savings and lives saved.44  It will take our 
collective investment—across all levels of government and 
the private sector—to address the substantial unmet 
HIV prevention need that has mounted in this country.  
2. 	Making Tough Choices about 
Directing Available Resources 
As the population in need of prevention services has 
continued to grow in the United States, CDC and the 
state and local partners it funds have been forced to do 
more with less. This has resulted in a “triage approach” 
to public health, in which only the most urgent priorities 
can be addressed. 
The nation has been and will increasingly be required to 
make difficult choices to ensure that available funds are 
having the greatest impact on infection rates. Resources 
must be directed to the populations at highest risk and to 
the strategies that are most cost-effective in reducing HIV 
transmission. As a nation, we must commit to using the 
best available science and knowledge to guide decision-
making at the national, state, and local levels. 
CDC is developing new tools to help determine the most 
effective combination of HIV prevention interventions for 
specific populations. These tools include: 
n New surveillance systems and analyses. CDC 
has developed innovative, technologically-advanced 
systems to track new HIV infections, monitor HIV risk 
behaviors, and measure access to effective inter­
ventions among high-risk populations. CDC is also 
working to develop, for the first time, estimates of 
HIV infection rates (cases per 100,000 population) 
by individual risk group (e.g., men who have sex with 
men, injection drug users, and high-risk 
heterosexuals). To date, this information has only 
been available for population subgroups assessed by 
the U.S. Census, such as men and women and racial 
and ethnic groups. The new data will allow health 
officials to more accurately estimate the health 
inequities affecting specific subpopulations (e.g., 
black MSM), and direct resources accordingly.   
n Cost-effectiveness models.  As data on the 

effectiveness and costs of a range of prevention 

approaches continue to accumulate, CDC is 

developing sophisticated models that will allow a 

more systematic and precise examination of the 

cost-effectiveness of specific approaches, help 

identify the best combination of available 

interventions, and indicate the most effective 





n Analysis of state and local resource targeting.
CDC and other partners are currently analyzing how 
well federal, state, and local resources are targeted to 
the geographic areas and populations that bear the 
greatest burden of HIV.  This information will help HIV 
prevention planners determine what changes may be 
necessary to ensure that resources are going where 






     
 






















 7 SECTION 3 | What Will Determine the Future Course of the U.S. HIV Epidemic  
3. Integrating New HIV Prevention 
Tools into Existing Programs 
While existing prevention tools have had a significant 
impact on the epidemic, there remains an urgent need for 
new prevention options to reduce the burden of HIV in 
the United States. CDC, the National Institutes of Health 
(NIH), and other research partners are evaluating 
promising new biomedical and behavioral approaches 
to HIV prevention. 
As new prevention interventions become available, it will 
be critical to use them not in isolation, but in combination 
with other proven interventions, especially since no single 
behavioral or biomedical intervention is likely to be 100 
percent effective against HIV infection. Biomedical and 
behavioral interventions will need to be delivered in 
tandem to ensure that all tools are maximized and avoid 
migration away from more effective approaches. 
A number of promising clinical trials focusing on biomedi­
cal strategies are likely to report results in the near future. 
These include: 
n Pre-exposure prophylaxis. CDC, NIH, and other 
research groups are currently investigating whether 
oral drugs used to treat HIV can be taken by HIV-
negative individuals to prevent them from becoming 
infected with the virus. Known as pre-exposure 
prophylaxis (PrEP), this strategy is being studied in 
clinical trials around the world. 
n Microbicides.  Researchers are examining whether 
the application of vaginal gels containing 
antiretroviral drugs can effectively prevent HIV 
transmission during sex. Clinical trials to investigate 
the effectiveness of several microbicide formulations 
in preventing heterosexual HIV transmission to 
women are currently underway. 
n Intensified HIV testing, combined with early HIV 
treatment.  Because HIV-infected individuals taking 
antiretroviral medications have lower levels of HIV 
in their blood than untreated individuals, researchers 
are investigating whether HIV-positive individuals in 
treatment are less likely than untreated individuals 
to transmit HIV.  CDC is supporting NIH in research 
to evaluate the potential feasibility and impact of 
expanded testing and treatment on prevention. 
CDC is also currently evaluating the potential role of adult 
male circumcision in slowing the U.S. epidemic. This tool 
was recently proven to reduce female-to-male transmission 
in African settings. While there are important differences 
in the routes of transmission and rates of circumcision in 
the United States and Africa, there may be some subpopu­
lations for whom this could offer additional protection. 
Moving forward, it will also be critical to identify effective 
interventions to address the root societal factors facilitating 
HIV transmission, including poverty, racism, and stigma.  
Finally, we must maximize opportunities to address other 
serious threats to health in those living with and at risk for 
HIV, including viral hepatitis, other STDs, and tuberculosis. 
In the fight to conquer HIV, we stand at a 
critical crossroads. Significant reductions 
in HIV are possible with a stronger response 
to the HIV epidemic in the United States. 
Unfortunately, without such a response, 
increases in new infections are also possible. 
The future of the HIV epidemic will depend 
on the choices we make today. 
“As a nation, now is the time to 
determine the direction we will take 
in fighting this serious – yet 
preventable – disease. One direction 
leads to complacency and the injustice 
of an HIV epidemic that affects the most 
vulnerable of Americans. The other 
turns toward a re-energized, 
science-driven effort to reduce the 
spread of HIV.  Public health and our 
national conscience require we make 
the right choice.” 
Dr. Jonathan Mermin 
Director, CDC’s Division of HIV/AIDS Prevention 
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